A look back at a memorable evening for the future of biotechnology and pain management. 

On Wednesday evening, Tafalgie Therapeutics had the immense pleasure of bringing together more than 150 shareholders, partners, and scientists at the Sky Center in Marseille. This exclusive event provided an opportunity to share our strategic progress and reaffirm our collective ambition.

The Research & Development session featured an exceptional presentation by Prof. Ardem Patapoutian, winner of the 2021 Nobel Prize in Medicine and a member of our Scientific Advisory Board. Ardem spoke about his longstanding relationship with Aziz Moqrich, our founder and Chief Scientific Officer, which began with their collaboration at the prestigious Scripps University in the United States, and then shared his deeply optimistic vision regarding the disruptive potential of Tafalgie’s scientific discoveries to transform patient care.
The clinical segment highlighted major milestones thanks to a presentation by Prof. Olivier Blin, founder and Chief Medical Officer of Tafalgie. He provided a promising update on the Tafafirst study, conducted with our first lead drug candidate.
To conclude this presentation, Eric Schettini, CEO and founder of Tafalgie Therapeutics, took the floor to analyze the current macroeconomic environment for biotechnology. In light of these challenges, he outlined the financial roadmap and ambitious corporate strategy that position Tafalgie as a key player in medical innovation.

A huge thank you to our shareholders for their continued trust and to all our teams who work every day to bring the medicine of tomorrow to life. . The adventure has only just begun!

photo by Patryck Lebrun